|
| 36288547 | Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 37015337 | NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. | J Natl Compr Canc Netw | 2023 |
| 37270692 | Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 36504141 | Trends in Stage I Lung Cancer. | Clin Lung Cancer | 2023 |
| 35298698 | First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. | Cancer Chemother Pharmacol | 2022 |
| 35545176 | Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35640927 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. | J Immunother Cancer | 2022 |
| 35419282 | Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. | Front Oncol | 2022 |
| 35815644 | Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. | Future Oncol | 2022 |
| 35618629 | Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. | Clin Lung Cancer | 2022 |
| 36179540 | Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. | Lung Cancer | 2022 |
| 35074432 | Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 35247086 | Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2022 |
| 33097414 | Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. | Clin Lung Cancer | 2021 |
| 33575203 | <i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis. | Front Oncol | 2021 |
| 33683919 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. | J Clin Oncol | 2021 |
| 33652156 | A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. | J Thorac Oncol | 2021 |
| 33643895 | <i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+). | Front Oncol | 2021 |
| 33668021 | NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. | J Natl Compr Canc Netw | 2021 |
| 35005654 | A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. | JTO Clin Res Rep | 2021 |
| 34591593 | Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. | J Clin Oncol | 2021 |
| 34809804 | Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation. | J Thorac Oncol | 2021 |
| 34426443 | Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. | Clin Cancer Res | 2021 |
| 34422335 | A phase II study of everolimus in patients with advanced solid malignancies with <i>TSC1, TSC2, NF1, NF2</i> or <i>STK11</i> mutations. | J Thorac Dis | 2021 |
| 34242790 | A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC. | J Thorac Oncol | 2021 |
| 34256279 | Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. | Eur J Cancer | 2021 |
| 33159216 | A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. | Cancer Chemother Pharmacol | 2021 |
| 31065954 | A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. | Invest New Drugs | 2020 |
| 31739184 | Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. | Lung Cancer | 2020 |
| 32857949 | Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer. | Cancer Cell | 2020 |
| 32245472 | Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014. | BMC Endocr Disord | 2020 |
| 32438272 | SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. | Lung Cancer | 2020 |
| 32228198 | Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancer. | Future Oncol | 2020 |
| 30487236 | A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. | Cancer Discov | 2019 |
| 31300452 | Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. | Clin Cancer Res | 2019 |
| 31231122 | RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. | Br J Cancer | 2019 |
| 31632798 | KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49. | J Thorac Dis | 2019 |
| 31446228 | An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. | Lung Cancer | 2019 |
| 31506387 | Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. | Clin Cancer Res | 2019 |
| 30933354 | Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy. | Cancer | 2019 |
| 26669741 | Immunogenicity of Influenza Vaccination in Patients With Cancer. | Am J Clin Oncol | 2018 |
| 30224629 | Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. | Nat Commun | 2018 |
| 30705863 | Role of immune checkpoint blockers in patients with <i>EGFR</i> mutation. | Transl Lung Cancer Res | 2018 |
| 30323087 | NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. | J Natl Compr Canc Netw | 2018 |
| 30285518 | First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. | J Clin Oncol | 2018 |
| 30413381 | Lorlatinib: a new-generation drug for ALK-positive NSCLC. | Lancet Oncol | 2018 |
| 30383906 | ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). | Cancer | 2018 |
| 29364287 | The biology and management of non-small cell lung cancer. | Nature | 2018 |
| 29526531 | Non-small-cell Lung Cancer With Brain Metastasis at Presentation. | Clin Lung Cancer | 2018 |
| 29410127 | Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. | J Thorac Oncol | 2018 |